Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, with significant revenue growth and a shift to GAAP profitability. Despite increased COGS, net income improved, and cash reserves grew. The Q&A section revealed positive reception of product labels and strategic market expansion plans. However, vague responses on revenue acceleration and supply stability pose some concerns. Overall, the positive financial results, optimistic guidance, and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
Key Financial Performance
Galafold Revenue Revenue reached $138.3 million, up 12% at constant exchange rates and up 15% in reported terms. Year-over-year, the underlying growth in patient demand increased by 13%. Reasons for growth include record demand, robust new patient starts, and a growing global market share of treated Fabry patients with amenable mutations.
Pombiliti and Opfolda Revenue Third quarter revenue reached $30.7 million, up 42% at constant exchange rates and up 45% in reported terms. Year-to-date, Pombiliti and Opfolda has grown 59% at CER and 61% in reported revenue. Reasons for growth include strong sales growth, high patient demand, and increasing market penetration in both established and new markets.
Total Revenue Total revenue for Q3 2025 was $169.1 million, a 19% increase over the same period in 2024. At constant exchange rates, revenue grew 17%. Reasons for growth include strong performance of Galafold and Pombiliti and Opfolda.
Cost of Goods Sold (COGS) COGS as a percentage of net sales was 12% for Q3 2025 compared to 9% in the same period last year. The increase is attributed to the hybrid year for Pombiliti and Opfolda COGS as previously expensed inventory was worked through during the first three quarters of 2025.
GAAP Net Income GAAP net income in Q3 2025 was $17.3 million or $0.06 per share compared to a net loss of $6.7 million or $0.02 per share in Q3 2024. This improvement is attributed to strong revenue growth and financial discipline.
Non-GAAP Net Income Non-GAAP net income in Q3 2025 was $54.2 million or $0.18 per share compared to $30.8 million or $0.10 per share in Q3 2024. Reasons for improvement include strong revenue growth and operational efficiency.
Cash Position Cash, cash equivalents, and marketable securities were $263.8 million as of September 30, 2025, compared to $249.9 million as of December 31, 2024. This represents a $32.8 million increase during the third quarter, attributed to positive cash generation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Galafold: Delivered 13% year-over-year patient growth, driven by record demand and robust new patient starts. Revenue reached $138.3 million, up 12% at constant exchange rates and 15% in reported terms. Achieved approximately 69% global market share of treated Fabry patients with amenable mutations. Sustained compliance and adherence rates above 90%.
Pombiliti and Opfolda: Revenue reached $30.7 million, up 42% at constant exchange rates and 45% in reported terms. Strong sales growth and high patient demand observed. Reimbursed in 15 countries, with new markets including Japan, Belgium, Ireland, and Luxembourg. Full-year revenue growth guidance of 50%-65% reiterated.
Geographic Expansion: Pombiliti and Opfolda reimbursed in 15 countries, including new markets like Japan, Belgium, Ireland, and Luxembourg. Strong execution in newer launch markets such as Switzerland, Italy, Czech Republic, Portugal, and the Netherlands.
Financial Performance: Achieved total revenue of $169.1 million in Q3 2025, a 19% increase year-over-year. Positive GAAP net income of $17.3 million in Q3 2025, compared to a net loss in Q3 2024. Cash position increased to $263.8 million as of September 30, 2025.
Operational Efficiency: Maintained gross margin in the mid-80s and achieved positive cash generation in Q3 2025. Non-GAAP operating expenses increased but remained within guidance.
Pipeline Development: Advanced DMX-200, a first-in-class therapy for FSGS, with the pivotal Phase III ACTION3 trial over 90% enrolled and on track for full enrollment by year-end. FDA alignment on proteinuria as the primary endpoint for approval.
Scientific Evidence: Presented new 4-year data from the PROPEL study, showing stability or improvement in muscle function and strength for Pombiliti and Opfolda. Real-world evidence and independent studies further support differentiation of these therapies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The company faces challenges in securing pricing and reimbursement agreements in various countries, as evidenced by the ongoing efforts to expand access to Pombiliti and Opfolda in new markets. This could delay revenue realization and market penetration.
Market Competition: The company acknowledges competitive pressures, particularly in the Pompe disease market, where patients are switching from existing treatments like Nexviazyme to Pombiliti and Opfolda. This indicates a need to continuously differentiate their products to maintain and grow market share.
Supply Chain and Cost Management: The hybrid year for Pombiliti and Opfolda COGS, with previously expensed inventory being worked through, suggests potential challenges in managing supply chain costs and ensuring consistent gross margins.
Economic and Currency Risks: Revenue growth is reported at constant exchange rates, highlighting exposure to currency fluctuations that could impact financial performance, especially given the significant portion of revenue generated outside the U.S.
Strategic Execution Risks: The company’s ambitious goals, such as achieving $1 billion in combined sales by 2028 and launching in up to 10 new countries in 2025, require flawless execution. Any missteps could impact long-term growth and shareholder value.
Clinical Development Risks: The development of DMX-200 for FSGS, while promising, is still in late-stage Phase III trials. Any delays or failures in achieving regulatory approval could hinder the company’s pipeline expansion and future revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to sustain double-digit revenue growth in its Fabry and Pompe core business into the years ahead. Full-year 2025 revenue growth guidance is reiterated at 15% to 22%.
Galafold Revenue: Galafold is projected to achieve 10% to 15% revenue growth in 2025, with a long-term goal of surpassing $1 billion in revenue. Key drivers include finding new patients, expanding into new markets, and sustaining compliance rates above 90%.
Pombiliti and Opfolda Revenue: Revenue growth for Pombiliti and Opfolda is expected to be 50% to 65% in 2025. The company plans to launch in up to 10 new countries in 2025 and maintain over 90% compliance rates.
Long-term Sales Target: The company reaffirms its confidence in achieving combined sales of $1 billion for its two commercial products, Galafold and Pombiliti/Opfolda, by 2028.
DMX-200 Development: The ACTION3 pivotal study for DMX-200, a therapy for FSGS, is over 90% enrolled and on track to complete enrollment by the end of 2025. The company anticipates further discussions with the FDA in early 2026.
Profitability: The company expects to achieve positive GAAP net income for the second half of 2025, though profitability may not be linear quarter-to-quarter.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the overall reception to the label for Pom-Op, especially in the U.S., and how is real-world evidence influencing prescription patterns?
A:The label for Pom-Op has been largely well-received in the U.S., with ongoing efforts to expand it to pediatric patients with late-onset and infantile-onset Pompe disease. Real-world evidence is becoming increasingly important in conversations with physicians, supported by long-term data and case studies that highlight the durability and effectiveness of Pom-Op. Indirect comparisons with Nexviazyme and compelling pediatric case studies are also influencing prescription patterns.
Q:What are the U.S. new patient starts in Q3, and what can be done to accelerate Pompe revenue growth by 2026?
A:Q3 saw the largest net commercial demand for Pombiliti and Opfolda, with significant growth in the U.S. due to improved reimbursement times and strong adherence rates. To accelerate revenue growth by 2026, the company plans to leverage real-world evidence, expand into new markets like Japan and the Netherlands, and continue building momentum through physician experience and data presentations.
Q:For Galafold, are the strongest patient adds coming from core or emerging countries?
A:The strongest patient adds for Galafold are primarily coming from core countries, driven by newly diagnosed naive patients with amenable mutations. There is also some growth from switches in recently launched markets, with Fabry disease remaining underdiagnosed.
Q:Is there a defined threshold for MCP-1 levels or other inflammatory markers that make patients good candidates for DMX-200?
A:There is no entry criterion for MCP-1 levels in the Phase III study, but higher MCP-1 levels are correlated with more robust responses to DMX-200. MCP-1 levels are being measured throughout the study, and patients with higher levels are expected to show greater impact.
Q:What impact may BIOSECURE 2.0 have on the usability of the Ireland plant PomOp product in the U.S., and how has physician feedback changed on the competitive dynamic in Pompe?
A:BIOSECURE 2.0 is not expected to impact the usability of the Ireland plant PomOp product in the U.S., as the company anticipates stable supply from the Ireland facility. Physician feedback on PomOp has been positive, with growing evidence and real-world data increasing comfort levels for switching patients to PomOp.
Q:When could the company potentially receive infantile-onset Pompe disease label expansion, and is it contingent on the ROSELLA trial?
A:The infantile-onset Pompe disease label expansion is contingent on the ROSELLA trial, with progress being made in both switch and naive patient cohorts. The label expansion for adolescent late-onset Pompe patients is expected mid-next year, with younger late-onset patients following in a couple of years, and infantile-onset expansion coming shortly after.
Q:How should we think about the commercial trajectory of PomOp versus this year, and what is the expected market share at steady state?
A:The commercial trajectory of PomOp is expected to show strong growth next year, with continued momentum into 2026. The company aims to establish PomOp as the leading product for Pompe disease, targeting over 50% market share at peak, which aligns with a $1 billion-plus peak potential.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about accelerating Pompe revenue growth by 2026, providing general strategies but no specific details. Similarly, the response to the question about BIOSECURE 2.0's impact on the Ireland plant product was vague, emphasizing confidence in supply stability without addressing potential challenges.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Belgium Ireland
DMX class
ERT
FSGS
ICIEM
Ireland Luxembourg
Japan Belgium
Opfolda COGS
Opfolda exchange
PROPEL
Phase III
PomOp
Pombiliti Opfolda
Sebastien Slide
Slide example
analysis
consensus sale
demand patient
enrollment end
line consensus
market end
muscle function
patient Japan
patient Myozyme
patient start
record demand
sale estimate
stability
stage
track enrollment
treatment option
FOLD Transcript
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights strong financial performance, with significant revenue growth and a shift to GAAP profitability. Despite increased COGS, net income improved, and cash reserves grew. The Q&A section revealed positive reception of product labels and strategic market expansion plans. However, vague responses on revenue acceleration and supply stability pose some concerns. Overall, the positive financial results, optimistic guidance, and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call reveals mixed signals. Financial performance shows increased expenses and net loss, though non-GAAP income remains positive. Product development and market expansion are promising, with strong market share gains and regulatory progress. However, the decreased revenue growth guidance and increased COGS raise concerns. The Q&A highlights confidence in IP and manufacturing progress but lacks specifics on timelines and COGS impact. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
FOLD Slides
FOLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
